Journal of Yeungnam Medical Science

Case report

Musculoskeletal Disorders
Unilateral lower extremity lymphedema followed by COVID-19 vaccination in patients with cervical cancer history: two case reports: Jae Ik Jung, Hee Kyung Cho; J Yeungnam Med Sci. 2025;42:23. Published online January 21, 2025; DOI: https://doi.org/10.12701/jyms.2025.42.23

1,674 View
111 Download

Abstract PDF: The coronavirus disease 2019 (COVID-19) pandemic prompted the development of messenger RNA vaccines. Following extensive vaccination campaigns worldwide, several adverse reactions to these vaccines have been reported. This is a case series of unilateral lower extremity lymphedema after COVID-19 vaccination in two patients with a history of cervical cancer. An 82-year-old woman and a 68-year-old woman visited the outpatient clinic with unilateral leg edema after receiving a COVID-19 booster vaccine (BNT162b2; Pfizer-BioNTech) in the deltoid muscle. Both patients had a common history of cervical cancer treated with surgery, chemotherapy, and radiotherapy and were in complete remission. Gynecological evaluations, including laboratory and imaging studies, revealed no specific findings. Lymphoscintigraphy revealed delayed lymphatic drainage with diffuse dermal backflow in a unilateral lower extremity. This case series explores adverse reactions to COVID-19 vaccination in patients who are at high risk of developing lymphedema, providing novel data for similar clinical presentations.

Review article

Infectious Disease
Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review: Jae Kyung Lee, Ok Sarah Shin; J Yeungnam Med Sci. 2022;39(2):89-97. Published online February 14, 2022; DOI: https://doi.org/10.12701/jyms.2021.01669

4,983 View
88 Download
2 Web of Science
2 Crossref

More than 2 years after the explosion of the coronavirus disease 2019 (COVID-19) pandemic, extensive efforts have been made to develop safe and efficacious vaccines against infections with severe acute respiratory syndrome coronavirus 2. The pandemic has opened a new era of vaccine development based on next-generation platforms, including messenger RNA (mRNA)-based technologies, and paved the way for the future of mRNA-based therapeutics to provide protection against a wide range of infectious diseases. Multiple vaccines have been developed at an unprecedented pace to protect against COVID-19 worldwide. However, important knowledge gaps remain to be addressed, especially in terms of how vaccines induce immunogenicity and efficacy in those who are elderly. Here, we discuss the various vaccine platforms that have been utilized to combat COVID-19 and emphasize how these platforms can be a powerful tool to react quickly to future pandemics.

Citations

Citations to this article as recorded by

Unilateral lower extremity lymphedema followed by COVID-19 vaccination in patients with cervical cancer history: two case reports
Jae Ik Jung, Hee Kyung Cho
Journal of Yeungnam Medical Science.2025; 42: 23. CrossRef
Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant
Waranyoo Phoolcharoen, Balamurugan Shanmugaraj, Narach Khorattanakulchai, Piyanate Sunyakumthorn, Sathit Pichyangkul, Pornnarin Taepavarapruk, Wanlapa Praserthsee, Suchinda Malaivijitnond, Suwimon Manopwisedjaroen, Arunee Thitithanyanont, Kanjana Srisutth
Vaccine.2023; 41(17): 2781. CrossRef

First
Prev
Page of 1
Next
Last

Search